A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19
- Registration Number
- NCT04522830
- Lead Sponsor
- Beech Tree Labs, Inc.
- Brief Summary
Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
- 40 years of age or older
- Provide written informed consent
- Have a SARS-COV-19 diagnostic test with positive results
Exclusion Criteria
- Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
- Subjects currently hospitalized
- Subjects who have received a COVID vaccination
- Subjects with a diagnosis of immunodeficiency
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BTL-TML-COVID BTL-TML-COVID BTL-TML-COVID Placebo Placebo Placebo
- Primary Outcome Measures
Name Time Method Mean duration and severity of disease Two days Change from baseline in the physical component summary of the short form-36 Quality of Life Instrument
- Secondary Outcome Measures
Name Time Method Incidence/Safety of Adverse Events Baseline through 10 days AEs will be assessed by the investigator as to severity, duration and relationship to treatment
Trial Locations
- Locations (1)
Intermountain Clinical Reserach
🇺🇸Draper, Utah, United States